Viridian Therapeutics Stock Price Prediction
| VRDN Stock | USD 18.13 1.07 6.27% |
Oversold Vs Overbought
48
Oversold | Overbought |
EPS Estimate Next Quarter (1.03) | EPS Estimate Current Year (3.99) | EPS Estimate Next Year (4.22) | Wall Street Target Price 40.4375 | EPS Estimate Current Quarter (1.06) |
Using Viridian Therapeutics hype-based prediction, you can estimate the value of Viridian Therapeutics from the perspective of Viridian Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Viridian Therapeutics using Viridian Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Viridian using crowd psychology based on the activity and movement of Viridian Therapeutics' stock price.
Viridian Therapeutics Implied Volatility | 0.85 |
Viridian Therapeutics' implied volatility exposes the market's sentiment of Viridian Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Viridian Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Viridian Therapeutics stock will not fluctuate a lot when Viridian Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Viridian Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Viridian because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Viridian Therapeutics after-hype prediction price | USD 18.11 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Viridian contract
Based on the Rule 16, the options market is currently suggesting that Viridian Therapeutics will have an average daily up or down price movement of about 0.0531% per day over the life of the 2025-04-17 option contract. With Viridian Therapeutics trading at USD 18.13, that is roughly USD 0.009632 . If you think that the market is fully incorporating Viridian Therapeutics' daily price movement you should consider acquiring Viridian Therapeutics options at the current volatility level of 0.85%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Viridian |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Viridian Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Viridian Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Viridian Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Viridian Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Viridian Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Viridian Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Viridian Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Viridian Therapeutics' historical news coverage. Viridian Therapeutics' after-hype downside and upside margins for the prediction period are 13.66 and 22.56, respectively. We have considered Viridian Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Viridian Therapeutics is not too volatile at this time. Analysis and calculation of next after-hype price of Viridian Therapeutics is based on 3 months time horizon.
Viridian Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Viridian Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Viridian Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Viridian Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.40 | 4.45 | 0.02 | 0.07 | 8 Events / Month | 16 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
18.13 | 18.11 | 0.11 |
|
Viridian Therapeutics Hype Timeline
Viridian Therapeutics is at this time traded for 18.13. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of -0.07. Viridian is forecasted to decline in value after the next headline, with the price expected to drop to 18.11. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.11%, whereas the daily expected return is at this time at -0.4%. The volatility of related hype on Viridian Therapeutics is about 2479.11%, with the expected price after the next announcement by competition of 18.06. About 100.0% of the company outstanding shares are owned by institutional investors. The book value of Viridian Therapeutics was at this time reported as 6.55. The company recorded a loss per share of 4.32. Viridian Therapeutics last dividend was issued on the 13th of November 2020. The entity had 1:15 split on the 13th of November 2020. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out Viridian Therapeutics Basic Forecasting Models to cross-verify your projections.Viridian Therapeutics Related Hype Analysis
Having access to credible news sources related to Viridian Therapeutics' direct competition is more important than ever and may enhance your ability to predict Viridian Therapeutics' future price movements. Getting to know how Viridian Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Viridian Therapeutics may potentially react to the hype associated with one of its peers.
Viridian Therapeutics Additional Predictive Modules
Most predictive techniques to examine Viridian price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Viridian using various technical indicators. When you analyze Viridian charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Viridian Therapeutics Predictive Indicators
The successful prediction of Viridian Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Viridian Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Viridian Therapeutics based on analysis of Viridian Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Viridian Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Viridian Therapeutics's related companies. | 2024 | 2025 (projected) | Dividend Yield | 8.52E-4 | 0.001448 | Price To Sales Ratio | 2.8K | 2.9K |
Story Coverage note for Viridian Therapeutics
The number of cover stories for Viridian Therapeutics depends on current market conditions and Viridian Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Viridian Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Viridian Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Viridian Therapeutics Short Properties
Viridian Therapeutics' future price predictability will typically decrease when Viridian Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Viridian Therapeutics often depends not only on the future outlook of the potential Viridian Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Viridian Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 44.8 M | |
| Cash And Short Term Investments | 477.4 M |
Check out Viridian Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share | Quarterly Revenue Growth 0.194 | Return On Assets | Return On Equity |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.